Exelixis (EXEL) Other Non-Current Liabilities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Other Non-Current Liabilities of $117.3 million in Q2 2026, up 12.36% quarter-over-quarter from $104.4 million in Q1 2026, and down 2.22% on a YoY basis from $120.0 million in Q2 2025.
Exelixis (EXEL) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $117.3 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 2.22% year-over-year to $117.3 million; the TTM figure through Apr 2026 stood at $117.3 million (down 2.22% YoY), while the FY2026 annual figure was $104.4 million, down 4.11% from the prior year.
- Other Non-Current Liabilities was $117.3 million for Q2 2026 at Exelixis, up from $104.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $128.6 million in Q3 2025 to a low of $1.9 million in Q3 2022.
- Historically, Other Non-Current Liabilities has averaged $82.1 million across 5 years, with a median of $96.1 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 53.35% in 2022, then soared 3129.35% in 2023.
- A 5-year view of Other Non-Current Liabilities shows it stood at $68.5 million in 2022, then surged by 37.49% to $94.2 million in 2023, then rose by 1.95% to $96.1 million in 2024, then climbed by 17.22% to $112.6 million in 2025, then climbed by 4.19% to $117.3 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $117.3 million (Q2 2026), $104.4 million (Q1 2026), and $112.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 117.33 Mn |
| Jan 2, 2026 | 104.42 Mn |
| Oct 3, 2025 | 112.61 Mn |
| Jul 4, 2025 | 128.59 Mn |
| Apr 4, 2025 | 120.00 Mn |
| Jan 3, 2025 | 108.90 Mn |
| Sep 27, 2024 | 96.07 Mn |
| Jun 28, 2024 | 109.67 Mn |
| Mar 29, 2024 | 101.27 Mn |
| Dec 29, 2023 | 94.22 Mn |
| Sep 29, 2023 | 61.62 Mn |
| Jun 30, 2023 | 73.50 Mn |
| Mar 31, 2023 | 67.38 Mn |
| Dec 30, 2022 | 68.53 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jul 1, 2022 | 17.40 Mn |
| Apr 1, 2022 | 12.52 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Oct 1, 2021 | 4.09 Mn |
| Jul 2, 2021 | 7.07 Mn |